Press Releases

Year

May 10, 2023

4D Molecular Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights

Presented positive interim data from intravitreal 4D-150 Phase 1/2 PRISM clinical trial for wet age-related macular degeneration (wet AMD) at the 2023 ARVO Annual Meeting On track for completion of enrollment of the Phase 2 Dose Expansion Stage of the PRISM clinical trial in Q3 Acquired all

May 9, 2023

4D Molecular Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Underwriters’ full exercise of option brings gross proceeds to $138.0 million EMERYVILLE, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting

May 8, 2023

4D Molecular Therapeutics to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large market diseases, announced today it will participate in the following

May 4, 2023

4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

EMERYVILLE, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large market diseases, announced today that it priced an upsized underwritten

May 4, 2023

4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock

April 27, 2023

4DMT Presents Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ARVO 2023

Intravitreal 4D-150 was well-tolerated with no inflammation in 14 of 15 patients and only trace mixed cells at a single timepoint in one patient; no dose-limiting toxicities, treatment-related serious adverse events (SAE) or hypotony reported across all three dose cohorts with follow-up of 24 – 64

April 24, 2023

4DMT Acquires Complement Pathway Inhibitor Payload for 4D-175 Product Candidate for Geographic Atrophy

4DMT acquires all world-wide rights to short-form human complement factor H (sCFH) from Aevitas Therapeutics, Inc.; technology invented at University of Pennsylvania Announces sCFH as payload for 4D-175 lead product candidate for geographic atrophy (GA); sCFH extensively characterized in 3 genetic

April 13, 2023

4DMT to Present Interim Data from 4D-150 Phase 1/2 PRISM Clinical Trial for Wet AMD at ARVO 2023, and Promotes Robert Kim, M.D. to Chief Medical Officer

Interim data to be presented in an oral presentation by Dr. Arshad M. Khanani, M.D., M.A., FASRS at the 2023 ARVO Annual Meeting on Thursday, April 27, 2023 at 11:30 a.m. ET Promoted Robert Kim, M.D. from SVP to Chief Medical Officer and Therapeutic Head, Ophthalmology Company to host live webcast

March 15, 2023

4D Molecular Therapeutics Reports Full Year 2022 Financial Results and Operational Highlights

Provided updates on clinical pipeline, including 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for cystic fibrosis lung disease, and 4D-310 for Fabry disease cardiomyopathy Demonstrated robust clinical gene delivery, tolerability and initial

February 22, 2023

4D Molecular Therapeutics Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials & Development Plans for Fabry Disease Cardiomyopathy at WORLDSymposium™

All three patients with 12 months of follow-up demonstrated improvement in multiple FDA-recommended cardiac endpoints at relatively low dose of 1E13 vg/kg Cardiac biopsy demonstrated selective and widespread transgene expression within ~50% of cardiomyocytes Engaging with FDA to lift clinical hold

Pagination

First page
Previous page
…
Page 2
Page 3
Current page 4
Page 5
Page 6
…
Next page
Last page

About 4DMT

Navigation

Location